Evidence map›Paper›PMID 33195038›Full record

ReviewFrontiers in chemistry2020

Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer.

Milad Ashrafizadeh, Mohammad Reza Bakhoda, Zahra Bahmanpour, Khandan Ilkhani, Ali Zarrabi, Pooyan Makvandi, Haroon Khan, Samaneh Mazaheri, Maryam Darvish, Hamed Mirzaei

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Cancer chemoprevention: signaling pathways and strategic approaches.Signal transduction and targeted therapy · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 4 countries.

Milad AshrafizadehDepartment of Basic Science, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran.
Mohammad Reza BakhodaStudent Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Zahra BahmanpourDepartment of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Khandan IlkhaniDepartment of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Ali ZarrabiSabanci University Nanotechnology Research and Application Center (SUNUM), Istanbul, Turkey.
Pooyan MakvandiCentre for Micro-BioRobotics, Istituto Italiano di Tecnologia, Pisa, Italy.
Haroon KhanDepartment of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan.
Samaneh MazaheriDepartment of Analytical Chemistry, Faculty of Chemistry, University of Kashan, Kashan, Iran.
Maryam DarvishDepartment of Medical Biotechnology, Faculty of Medicine, Arak University of Medical Science, Arak, Iran.
Hamed MirzaeiResearch Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.
Tabriz University of Medical Sciences · IRAbdul Wali Khan University Mardan · PKArak University of Medical Sciences · IRItalian Institute of Technology · ITKashan University of Medical Sciences · IRSabancı Üniversitesi · TRShahrekord University of Medical Sciences · IRUniversity of Kashan · IRUniversity of Tabriz · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is the most lethal malignancy of the gastrointestinal tract. Due to its propensity for early local and distant spread, affected patients possess extremely poor prognosis. Currently applied treatments are not effective enough to eradicate all cancer cells, and minimize their migration. Besides, these treatments are associated with adverse effects on normal cells and organs. These therapies are not able to increase the overall survival rate of patients; hence, finding novel adjuvants or alternatives is so essential. Up to now, medicinal herbs were utilized for therapeutic goals. Herbal-based medicine, as traditional biotherapeutics, were employed for cancer treatment. Of them, apigenin, as a bioactive flavonoid that possesses numerous biological properties (e.g., anti-inflammatory and anti-oxidant effects), has shown substantial anticancer activity. It seems that apigenin is capable of suppressing the proliferation of cancer cells

Indexed as

apigeninapoptosisoxidative stresspancreatic cancertherapy

Identifiers

PMID33195038
PMCPMC7593821
OpenAlexW3093318878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.